Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients.
10.1016/j.apsb.2022.08.018
- Author:
Solène MARIE
1
;
Kayla L FROST
1
;
Raymond K HAU
1
;
Lucy MARTINEZ-GUERRERO
1
;
Jailyn M IZU
1
;
Cassandra M MYERS
1
;
Stephen H WRIGHT
2
;
Nathan J CHERRINGTON
1
Author Information
1. College of Pharmacy, Department of Pharmacology & Toxicology, University of Arizona, Tucson, AZ 85721, USA.
2. College of Medicine, Department of Physiology, University of Arizona, Tucson, AZ 85724, USA.
- Publication Type:Review
- Keywords:
Adverse drug reaction;
Drug–drug interaction;
Enzyme;
Hepatic elimination;
Liver;
Non-alcoholic steatohepatitis;
Pharmacokinetics;
Transporter
- From:
Acta Pharmaceutica Sinica B
2023;13(1):1-28
- CountryChina
- Language:English
-
Abstract:
The liver plays a central role in the pharmacokinetics of drugs through drug metabolizing enzymes and transporters. Non-alcoholic steatohepatitis (NASH) causes disease-specific alterations to the absorption, distribution, metabolism, and excretion (ADME) processes, including a decrease in protein expression of basolateral uptake transporters, an increase in efflux transporters, and modifications to enzyme activity. This can result in increased drug exposure and adverse drug reactions (ADRs). Our goal was to predict drugs that pose increased risks for ADRs in NASH patients. Bibliographic research identified 71 drugs with reported ADRs in patients with liver disease, mainly non-alcoholic fatty liver disease (NAFLD), 54 of which are known substrates of transporters and/or metabolizing enzymes. Since NASH is the progressive form of NAFLD but is most frequently undiagnosed, we identified other drugs at risk based on NASH-specific alterations to ADME processes. Here, we present another list of 71 drugs at risk of pharmacokinetic disruption in NASH, based on their transport and/or metabolism processes. It encompasses drugs from various pharmacological classes for which ADRs may occur when used in NASH patients, especially when eliminated through multiple pathways altered by the disease. Therefore, these results may inform clinicians regarding the selection of drugs for use in NASH patients.
